Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Pastimes : Deadheads -- Ignore unavailable to you. Want to Upgrade?

To: JakeStraw who wrote (21137)	6/21/2000 2:48:00 PM
From: SIer formerly known as Joe B.	Read Replies (1) \| Respond to of 49843

That's cool. Study Shows Significant Improvement in Performance with Masimo SET Pulse Oximetry on Children in Postanesthesia Care Unit IRVINE, Calif., June 21 /PRNewswire/ -- A pulse oximetry reliability study on children in the postanesthesia care unit (PACU) was published in this month's edition of Anesthesia and Analgesia (Anesth Analg 2000;90:1336-40). The study showed that Masimo SET significantly improves detection of true hypoxemic events while dramatically reducing false alarms. The study was conducted by Shobha Malviya, MD, Paul Reynolds, MD, Terri Voepel-Lewis, BSN, MS, Monica Siewert, BA, David Watson, MD, Alan Tait, PhD, and Kevin Tremper, PhD, MD at the University of Michigan Health System, Ann Arbor Michigan. The University of Michigan researchers compared Masimo SET to conventional pulse oximetry from Nellcor, the N200, which has been the most commonly used pulse oximeter. Seventy-five children were monitored for a total of 42 hours and the results showed that Masimo SET pulse oximeters reduced false alarms by 60%, yet caught 100% of the hypoxemic events (true alarms). The Nellcor pulse oximeter missed 41% of the hypoxemic events. Some of the hypoxemic events missed by the Nellcor pulse oximeter lasted up to four minutes, which is long enough to cause death or brain damage. In discussing these results, the researchers wrote, "The single most important characteristic of a pulse oximeter is to identify all episodes of hypoxemia (i.e., high sensitivity) to permit intervention before the development of clinically significant hypoxemia. Failure to capture these episodes may result in fewer alarms, but may also lead to a false sense of security, and thereby delay appropriate intervention ... In our study, each episode of (Masimo SET) device-detected hypoxemia responded appropriately to treatment (e.g., administration of oxygen or patient stimulation)." In addition to the importance of sensitivity in detecting true alarms, the researchers discussed the impact of a high rate of false alarms. "A high incidence of FAs (false alarms) in pulse oximetry may lead to complacency of care by providers who have become desensitized to alarms. This may result in delays in response to clinical events." "It is great to see this excellent research published in Anesthesia and Analgesia," stated Joe E. Kiani, President and CEO of Masimo Corporation. "This is an important study not just for Masimo, but for all patients. There has been a recent mandate in the U.S. to reduce mortality and morbidity due to human errors. It's evident from the large body of clinical studies on Masimo SET that some of the errors can be simply reduced by upgrading from conventional pulse oximetry to Masimo SET. Conventional pulse oximeters fail to work when they are needed; this can lead to morbidity and death. If Masimo SET was used on all patients in every hospital, I am convinced that lives could be saved and/or improved. Masimo SET has been clinically proven over the last five years to work when it's needed most. This study, along with the neonatal study published in the May edition of the Journal of Critical Care Medicine and Dr. Barker's latest study on 17 pulse oximeters presented at the World Congress of Anesthesia two weeks ago, all offer compelling proof that Masimo SET pulse oximetry dramatically reduces false alarms. More importantly, it does so while identifying the true alarms that conventional pulse oximeters miss." Dr. Kevin K. Tremper, Chief of Anesthesiology at the University of Michigan, commented, "Masimo has truly made a contribution with its Signal Extraction Technology. Now it's up to my peers in the clinical community to use this breakthrough technology throughout the continuum of care for the betterment of patients." Masimo Corporation is a privately held medical technology company that designs, develops and licenses advanced medical signal processing and sensor technology for the noninvasive monitoring of vital physiological parameters. Masimo has created a fundamentally unique method, Signal Extraction Technology, to measure signals in the presence of noise. The first product this technology has been applied to is pulse oximetry. Pulse oximetry monitors the arterial oxygen saturation and pulse rate of patients. Masimo Signal Extraction pulse oximetry is the only technology clinically proven accurate during patient motion and low perfusion. To date, Masimo has licensed its Signal Extraction pulse oximetry OEM boards and proprietary single patient adhesive and reusable sensors to over 35 international patient monitoring system providers which make up approximately 50% of the world's pulse oximeter shipments. Masimo is located in Irvine, California. Additional information about Masimo and its products can be found on the company's web site at masimo.com. SOURCE Masimo Corporation -0- 06/21/2000 /CONTACT: Brad Langdale of Masimo Corporation, 949-253-6404/ /Web site: masimo.com CO: Masimo Corporation ST: California IN: MTC SU: PDT * end of story *